Business News

Announcement of the Presentation of Interim Results for Phase I Clinical Study of a Combination of OTSGC-A24 and Immune Checkpoint Inhibitor in Patients with Gastric Cancer

Publication of a paper describing Phase II study of cancer peptide vaccine S-588410 in urothelial carcinoma

Publication of a paper describing the synergistic effect of OTS167 and FLT3 inhibitors on acute myeloid leukemia

Publication of a paper describing a phase 2 study of cancer vaccination therapy in patients with refractory/persistent cervical cancer and ovarian cancer

Publication of a paper describing a pilot study of peptide vaccines for patients with malignant glioma

Publication of a paper describing the antitumor effect of MELK inhibitor OTS167 on ovarian cancer

Publication of a scientific paper about exploratory study of cancer peptide vaccine S-588410

Publication of a paper describing the anti-cancer effect of TOPK inhibitor OTS514 on multiple myeloma

Announcement of the presentation of results for exploratory study of peptide vaccine S-588410 at the 57th Annual Meeting of Japan Society of Clinical Oncology

Announcement of a commissioned basic contract between OTS’s subsidiary company and Cosmo Bio Co., Ltd. for peptide synthesis

Announcement of website release of our subsidiary company

Announcement of the article related our Special Scientific Advisor in Japan Times

Presentation Material of R&D Meeting 2017 (in Japanese)

Presentation Material of R&D Meeting 2016 (in Japanese)

Issuing ’Shareholder’s News December, 2016’(in Japanese)

Issuing ’Shareholder’s News June, 2016’(in Japanese)

Announcement of “Cancer Precision Medicine”

Commencement of “Neoantigen Dendritic Cells vaccine therapy”

Presentation Material of R&D Meeting 2015　(in English)

Posting on the March issue of Nature’s BioPharma Dealmakers